Major Events - Yunzhisheng (09678) is actively exploring new sustainable business models and project opportunities [1] - Junshi Biosciences (01877) achieved the primary endpoint in the Phase III clinical study of anti-IL-17A monoclonal antibody for moderate to severe plaque psoriasis [1] - Hutchison China MediTech (00013) will present the latest data on several self-developed compounds at the 2025 World Lung Cancer Congress and the 2025 Annual Meeting of the Chinese Society of Clinical Oncology [1] - InnoCare Pharma-B (09606) reached the primary endpoint in the Phase III clinical trial of DB-1303/BNT323 for HER2-positive unresectable or metastatic breast cancer patients [1] - Heng Rui Medicine (01276) plans to license its Class 1 innovative drug HRS-1893 to Braveheart Bio to expand into overseas markets [1] Financial Data - Aoyuan Group (01813) reported a pre-sale amount of 611 million yuan in August, a year-on-year decrease of 13.9% [1] - GAC Group (02238) sold 135,700 vehicles in August, a year-on-year decline of 8.43% [1] - Zhongliang Holdings (02772) recorded a cumulative contract sales amount of approximately 8.29 billion yuan in the first eight months, a year-on-year decrease of 32.71% [1] - Xiehe New Energy (00182) reported a total equity power generation of 507.64 GWh in August, a year-on-year increase of 6.07% [1] - Zhengrong Real Estate (06158) had a cumulative contract sales amount of approximately 2.99 billion yuan in the first eight months, a year-on-year decrease of 30.8% [1]
港股公告掘金 | 和黄医药将于2025年世界肺癌大会和中国临床肿瘤学会2025年年会公布自主研发的化合物的数项研究的最新数据